 |
|
Risk of Hemolytic Uremic Syndrome After Antibiotic Treatment of Escherichia coli O157:H7 Enteritis
A Meta-analysis
Nasia Safdar, MD;
Adnan Said, MD;
Ronald E. Gangnon, PhD;
Dennis G. Maki, MD
JAMA. 2002;288:996-1001.
Context The use of antibiotics for treatment of Escherichia coli O157:H7 infection has become controversial since a recent small study found that it may increase the risk of hemolytic uremic syndrome (HUS). However, other larger studies have reported a protective effect or no association.
Objective To determine whether antibiotic therapy for E coli O157:H7 enteritis increases the risk of HUS.
Data Sources PubMed and MEDLINE computer searches were performed for studies published from January 1983 to February 2001 using the key words hemolytic uremic syndrome, risk factor, antibiotics, and Escherichia coli O157:H7. Reference lists of relevant publications were reviewed, and 12 experts in the field were contacted to identify additional reports. No language restrictions were applied to the search.
Study Selection Studies were included if they reported a series of patients with documented E coli O157:H7 enteritis, some of whom developed HUS; had clear definitions of HUS; and had adequate data delineating the relationship between antibiotic therapy and the occurrence of HUS. Nine of the 26 identified studies fulfilled these criteria.
Data Extraction Two authors (N.S. and A.S.) independently reviewed each report identified by the searches and recorded predetermined information relevant to the inclusion criteria. A pooled odds ratio was calculated using a fixed-effects model, with assessment of heterogeneity among the studies.
Data Synthesis The pooled odds ratio was 1.15 (95% confidence interval, 0.79-1.68), indicating that there does not appear to be an increased risk of HUS with antibiotic treatment of E coli O157:H7 enteritis. Incomplete reporting of data in individual studies precluded adjustment for severity of illness.
Conclusion Our meta-analysis did not show a higher risk of HUS associated with antibiotic administration. A randomized trial of adequate power, with multiple distinct strains of E coli O157:H7 represented, is needed to conclusively determine whether antibiotic treatment of E coli O157:H7 enteritis increases the risk of HUS.
Author Affiliations: Section of Infectious Diseases, Department of Medicine (Drs Safdar and Maki), Section of Gastroenterology (Dr Said), and Department of Biostatistics and Medical Informatics (Dr Gangnon), University of Wisconsin Medical School and University of Wisconsin Hospital and Clinics, Madison.
RELATED ARTICLE
Antimicrobial Therapy in Patients With Escherichia coli O157:H7 Infection
Kåre Mølbak, Paul S. Mead, and Patricia M. Griffin
JAMA. 2002;288(8):1014-1016.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Rifaximin Does Not Induce Toxin Production or Phage-Mediated Lysis of Shiga Toxin-Producing Escherichia coli
Ochoa et al.
Antimicrob. Agents Chemother. 2007;51:2837-2841.
ABSTRACT
| FULL TEXT
The Use of Systemic Fluoroquinolones
Committee on Infectious Diseases
Pediatrics 2006;118:1287-1292.
ABSTRACT
| FULL TEXT
Laboratory-based surveillance of human verocytotoxigenic Escherichia coli infection in the Republic of Ireland, 2002-2004
Carroll et al.
J Med Microbiol 2005;54:1163-1169.
ABSTRACT
| FULL TEXT
Haemolytic uraemic syndrome due to ciprofloxacin-resistant Shigella dysenteriae serotype 1
Taneja et al.
J Med Microbiol 2005;54:997-998.
ABSTRACT
| FULL TEXT
Hemolytic Uremic Syndrome
Noris and Remuzzi
J. Am. Soc. Nephrol. 2005;16:1035-1050.
FULL TEXT
Use of antibiotics in suspected haemolytic-uraemic syndrome
Phillips et al.
BMJ 2005;330:409-410.
FULL TEXT
In vitro bactericidal activity of antimicrobial agents against enterohaemorrhagic Escherichia coli
Oie et al.
J Antimicrob Chemother 2004;54:897-903.
ABSTRACT
| FULL TEXT
Antibody Therapy in the Management of Shiga Toxin-Induced Hemolytic Uremic Syndrome
Tzipori et al.
Clin. Microbiol. Rev. 2004;17:926-941.
ABSTRACT
| FULL TEXT
Acute Infectious Diarrhea
Thielman and Guerrant
NEJM 2004;350:38-47.
FULL TEXT
Long-term Renal Prognosis of Diarrhea-Associated Hemolytic Uremic Syndrome: A Systematic Review, Meta-analysis, and Meta-regression
Garg et al.
JAMA 2003;290:1360-1370.
ABSTRACT
| FULL TEXT
Nonpathogenic Escherichia coli Can Contribute to the Production of Shiga Toxin
Gamage et al.
Infect. Immun. 2003;71:3107-3115.
ABSTRACT
| FULL TEXT
Risk of Hemolytic Uremic Syndrome From Antibiotic Treatment of Escherichia coli O157:H7 Colitis
Gill et al.
JAMA 2002;288:3110-3112.
FULL TEXT
Antimicrobial Therapy in Patients With Escherichia coli O157:H7 Infection
Molbak et al.
JAMA 2002;288:1014-1016.
FULL TEXT
|
